Current and emerging options in the treatment of onychomycosis

Boni Elewski, David Pariser, Phoebe Rich, Richard K. Scher

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Currently approved options for the treatment of onychomycosis include systemic therapy (the antifungal agents fluconazole, itraconazole, and terbinafine), topical agents (ciclopirox, which has been available since 1996, efinaconazole, currently pending approval), and laser systems. Phase III studies on another topical, tavaborole, have been completed and this medication also shows promise. Mechanical modalities are sometimes used but are seldom necessary. Recurrence of infection is common; the risk for recurrence may be reduced by adherence to preventive measures, especially avoiding (if possible) or promptly treating tinea pedis infections.

Original languageEnglish (US)
Pages (from-to)S9-S12
JournalSeminars in cutaneous medicine and surgery
StatePublished - Jun 1 2013


  • Ciclopirox
  • Efinaconazole
  • Fluconazole
  • Fungal infections
  • Itraconazole
  • Nail infections
  • Onychomycosis
  • Tavaborole
  • Terbinafines

ASJC Scopus subject areas

  • Surgery
  • Dermatology


Dive into the research topics of 'Current and emerging options in the treatment of onychomycosis'. Together they form a unique fingerprint.

Cite this